EKTA.B

48.7

+1.59%↑

EKTA.B

48.7

+1.59%↑

EKTA.B

48.7

+1.59%↑

EKTA.B

48.7

+1.59%↑

EKTA.B

48.7

+1.59%↑

Search

Vivesto AB

Cerrado

0

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave

By Trading Economics

Ingresos

-1.2M

-9.5M

BPA

-0.018

Empleados

4

Dividendos

By Dow Jones

Próximas Ganancias

11 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-2.7M

127M

Apertura anterior

0

Cierre anterior

0

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 oct 2025, 21:10 UTC

Principales Movimientos del Mercado

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 oct 2025, 19:03 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 oct 2025, 17:58 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 oct 2025, 17:12 UTC

Ganancias

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 oct 2025, 17:12 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 oct 2025, 16:59 UTC

Adquisiciones, fusiones, absorciones

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 oct 2025, 23:44 UTC

Charlas de Mercado

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:15 UTC

Ganancias

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 oct 2025, 22:02 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:02 UTC

Charlas de Mercado

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Health Care Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 oct 2025, 20:20 UTC

Ganancias

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 oct 2025, 20:08 UTC

Adquisiciones, fusiones, absorciones

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 oct 2025, 19:37 UTC

Adquisiciones, fusiones, absorciones

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 oct 2025, 19:26 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 oct 2025, 19:23 UTC

Charlas de Mercado

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 oct 2025, 19:23 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 18:35 UTC

Charlas de Mercado
Ganancias

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 oct 2025, 16:57 UTC

Charlas de Mercado

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
help-icon Live chat